What is Cempra?
Headquartered in Chapel Hill, North Carolina, Cempra, Inc. operates as a clinical-stage pharmaceutical entity dedicated to the discovery and development of next-generation anti-infectives. The company's core competency lies in its robust macrolide platform, which supports the development of solithromycin and fusidic acid. These candidates are currently undergoing rigorous Phase III clinical trials to address community-acquired bacterial pneumonia and acute bacterial skin infections. Beyond its primary focus on infectious diseases, Cempra is exploring the therapeutic potential of its proprietary compounds for non-infectious conditions, including diabetic gastroparesis, thereby diversifying its clinical portfolio and market reach.
How much funding has Cempra raised?
Cempra has raised a total of $194M across 8 funding rounds:
Series B
$10M
Private Equity
$25.5M
Series C
$46M
Debt
$5M
Stock Offering
$50.4M
Private Equity
$25.1M
Private Equity
$10M
Series A
$22M
Series B (2007): $10M with participation from I. Wistar Morris III, Optimer Pharmaceuticals, Intersouth Partners, and Aisling Capital
Private Equity (2009): $25.5M, investors not publicly disclosed
Series C (2009): $46M, investors not publicly disclosed
Debt (2011): $5M, investors not publicly disclosed
Stock Issuance/Offering (2012): $50.4M, investors not publicly disclosed
Private Equity (2012): $25.1M, investors not publicly disclosed
Private Equity (2016): $10M led by Toyama Chemical
Series A (2020): $22M supported by I. Wistar Morris and Intersouth Partners
Key Investors in Cempra
Toyama Chemical
Toyama Chemical Co., Ltd. is a core company of the Fujifilm Group responsible for the treatment area of Fujifilm's healthcare business, focusing on innovative medicines for infectious and inflammatory diseases.
Aisling Capital
Aisling Capital is a leading investment firm specializing in companies that develop and commercialize innovative healthcare products, services, and technologies, with a focus on biopharmaceutical development.
Intersouth Partners
Intersouth Partners is a venture capital firm that provides early-stage and growth-stage financing to companies in the life sciences and technology sectors.
What's next for Cempra?
With the recent capital injection, Cempra is well-positioned to accelerate its late-stage clinical programs and strengthen its commercialization readiness. The strategic focus remains on the successful completion of Phase III trials for its lead candidates, which are essential for regulatory approval and subsequent market entry. Furthermore, the company is expected to leverage its collaborative research agreements to expand the utility of its macrolide platform. As Cempra transitions from a development-heavy organization to a potential commercial-stage player, the focus will likely shift toward optimizing manufacturing capabilities and establishing strategic partnerships to ensure the effective distribution of its anti-infective solutions across North American markets.
See full Cempra company page
